SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

SMS Pharmaceuticals Ltd (SMSPHARMA) Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating

BSE: 532815 NSE: SMSPHARMA | Pharmaceuticals & Drugs | Small Cap

SMS Pharmaceuticals Share Price

427.60 3.45 (0.81%)
As on 17-Apr'26 16:59

SMS Pharmaceuticals Ltd (SMSPHARMA)

BSE: 532815 NSE: SMSPHARMA
Key Metrics
Market Cap
₹4,005 Cr.
P/E Ratio
45.87
Price to Book (P/B)
5.11
Price to Sales (P/S)
4.46
EV/EBITDA
23.56
Return on Capital Employed (ROCE)
12.20%
Current Price
₹427.6
Return on Equity (ROE)
11.41%
Return on Assets (ROA)
5.97%
Operating Profit Margin
17.9%
Net Profit Margin
8.74%
Gross Profit Margin
15.1%
Book Value per Share
₹83.7
Sales Growth (YoY)
10.36%
Sales Growth (3 Years)
14.62%
Operating Profit Growth (1 Year)
19.65%
Operating Profit Growth (3 Years)
6.84%
Net Profit Growth (1 Year)
38.37%
52-Week Low / High
₹205 / 447
Net Profit Growth (3 Years)
0.17%
Dividend Yield
0.19%
Promoter Holding
68.07%
Pledged shares (%)
of Promoter's holding (%)
17.99%

Check Before You Invest

Q.1 Revenue growth of SMS Pharmaceuticals Ltd?
SMS Pharmaceuticals Ltd revenue growth is 10.4% for FY-2025 , which is below its 5 year CAGR of 13.7% , indicating slower growth.
Q.1 Promoter shareholding and pledge status of SMS Pharmaceuticals Ltd?
Promoters hold 68.07% of the SMS Pharmaceuticals Ltd, with 17.99% of their stake pledged, indicating high pledge risk.
Q.1 Revenue growth of SMS Pharmaceuticals Ltd vs industry peers?
SMS Pharmaceuticals Ltd revenue CAGR is 13.70% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Q.1 Which industry/sub-sector does SMS Pharmaceuticals Ltd belong to?
SMS Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.1 Stock return of SMS Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 17.5% based on the current price.

DeciZen - make an informed investing decision on SMS Pharmaceuticals

Based on:

Overall Rating
Login to view analysis.

1. Quality


Login to view analysis.

2. Valuation


Login to view analysis.

3. Price Trend


Login to view analysis.

SMS Pharmaceuticals stock performance

Key Ratios
mw4me loader

Is SMS Pharmaceuticals Ltd an attractive stock to invest in?


Login to view analysis.

10 Year X-Ray : Login to view analysis.

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
SMS Pharmaceuticals Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good

Value Creation

Value Creation Index Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
ROCE % 16%12.6%17.7%16%12.6%17.1%12.3%3.7%11.3%12.2%-
Value Creation
Index
0.1-0.10.30.1-0.10.2-0.1-0.7-0.2-0.1-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 603438463465412563520522709783897
Sales YoY Gr.--27.4%5.6%0.5%-11.4%36.7%-7.7%0.4%35.9%10.4%-
Adj EPS 4.94.24.74.83.77.27.80.25.67.39.3
YoY Gr.--14.6%13.2%2.1%-22.8%92.5%9.2%-98%3400%30.5%-
BVPS (₹) 34.83135.640.243.450.658.358.56474.183.7
Adj Net
Profit
41.335.339.940.831.560.666.21.447.464.887
Cash Flow from Ops. 61.273.531.849.839.790.545.122.550.181.7-
Debt/CF from Ops. 3.324.62.93.82.85.811.35.63.8-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 2.9%13.7%14.6%10.4%
Adj EPS 4.6%14.5%-2.2%30.5%
BVPS8.8%11.3%8.3%15.8%
Share Price 17.4% 25% 80% 97.4%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25TTM
Return on
Equity %
1512.714.212.78.915.214.40.38.910.411.8
Op. Profit
Mgn %
14.817.220.219.419.421.522.110.516.517.919.2
Net Profit
Mgn %
6.98.18.68.87.610.812.70.36.78.39.7
Debt to
Equity
0.70.60.50.40.40.60.50.50.50.5-
Working Cap
Days
131160128152198167215256227234111
Cash Conv.
Cycle
42424367918212315212613747

Recent Performance Summary

Login to view analysis.
Login to view analysis.

Latest Financials

Standalone Consolidated
TTM EPS (₹) 9.3 9.6
TTM Sales (₹ Cr.) 897 897
BVPS (₹) 83.7 80.4
Reserves (₹ Cr.) 774 743
P/BV 5.11 5.32
PE 45.87 44.70
From the Market
52 Week Low / High (₹) 205.30 / 446.50
All Time Low / High (₹) 7.21 / 446.50
Market Cap (₹ Cr.) 4,005
Equity (₹ Cr.) 9.4
Face Value (₹) 1
Industry PE 42.1

Management X-Ray

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *19.5119.4019.4019.4019.4037.6032.4934.6517.9917.99
* Pledged shares as % of Promoter's holding (%)

Valuation of SMS Pharmaceuticals - Standalone Basis

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

YTD 1Y 3Y 5Y 10Y Max
mw4me loader

mw4me loader

Event Update

Login/Register to view analysis.

Analyst's Notes

data not found
No data found!

Key Ratios

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Sales603438463465412563520522709783
Operating Expenses + 514363369375332442405467592643
Manufacturing Costs722935353440586485100
Material Costs385296290293246340275336424436
Employee Cost 38273336394151505770
Other Costs 19121211122120182637
Operating Profit 897593908012111555117140
Operating Profit Margin (%) 14.8%17.1%20.2%19.4%19.4%21.5%22.1%10.5%16.5%17.9%
Other Income + 4123535546
Exceptional Items 0000000000
Interest 17161512121119222419
Depreciation 19192019222232323234
Profit Before Tax 5642606251916966693
Tax 15620211830111725
Profit After Tax 4236404133616844968
PAT Margin (%) 6.9%8.1%8.7%8.9%7.9%10.8%13.1%0.8%7.0%8.7%
Adjusted EPS (₹)4.94.24.84.93.97.28.00.55.87.7
Dividend Payout Ratio (%)4%5%5%5%6%4%4%62%7%5%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25

Equity and Liabilities

Shareholders Fund + 294263301340367428494495542657
Share Capital 8888888889
Reserves 286254293331359420485487533648
Debt +186134130133129218217215236264
Long Term Debt11374716268147150121122139
Short Term Debt7360587161716894114125
Minority Interest0000000000
Trade Payables84673948446573107151114
Others Liabilities 924762709513411497154171
Total Liabilities 6565105325906368468989141,0831,206

Fixed Assets

Net Fixed Assets +370290279281280457438412437533
Gross Block433310318340361559570576631760
Accumulated Depreciation6319395880101132164193227
CWIP 13881842711333035
Investments 21374545454545454545
Inventories11393107136129138251223234285
Trade Receivables612124264910649148236203
Cash Equivalents 1512131510414773642
Others Assets 63495568815358456464
Total Assets 6565105325906368468989141,0831,206

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Cash Flow From Operating Activity + 61733250409045225082
PBT 5642606251916966693
Adjustment 28323127292850535451
Changes in Working Capital -19-48-26-28-12-58-31-55-43
Tax Paid -22-9-11-13-12-16-15-5-15-20
Cash Flow From Investing Activity + -97-39-17-35-43-152-27-30-52-123
Capex -89-23-9-35-43-152-27-30-52-123
Net Investments -8-16-80-0-0-0-0-0-0
Others 0000000000
Cash Flow From Financing Activity + 44-33-15-13-292-12-323147
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 35-11-2-15188812-34720
Interest Paid -8-12-10-8-6-6-18-21-22-17
Dividend Paid -2-2-2-3-40-3-3-3-3
Others 20-8-112-1110-4254848
Net Cash Flow 9102-5316-39295

Finance Ratio

PARTICULARSMar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23Mar'24Mar'25
Ratios
ROE (%)15.1712.7914.3512.939.2415.3214.760.839.5311.41
ROCE (%)15.9512.6117.6615.9612.5717.0712.263.6711.2512.2
Asset Turnover Ratio1.050.780.960.90.740.820.640.610.770.74
PAT to CFO Conversion(x)1.452.030.81.221.211.480.665.51.021.21
Working Capital Days
Receivable Days35331718304651659295
Inventory Days5882738910780128157109112
Payable Days6993675468599298111111

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

SMS Pharmaceuticals Ltd FAQs

The current trading price of SMS Pharmaceuticals on 17-Apr-2026 16:59 is ₹427.6.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 16-Apr-2026 the market cap of SMS Pharmaceuticals stood at ₹4,004.6 Cr

The latest P/E ratio of SMS Pharmaceuticals as of 16-Apr-2026 is 45.87.

The latest P/B ratio of SMS Pharmaceuticals as of 16-Apr-2026 is 5.11.

The 52-week high of SMS Pharmaceuticals is ₹446.5 and the 52-week low is ₹205.3.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of SMS Pharmaceuticals is ₹897 ( Cr.) .

About SMS Pharmaceuticals Ltd

SMS Pharmaceuticals Ltd. is a global player in API manufacturing having strong research and manufacturing team supported by state of art facilities. What started off as a single facility single product manufacturing company in 1990 grew to be a multi location group having product list spreading across an array of therapeutic segments. SMS is currently a listed company having ever appreciating international and domestic customer base. Having six multi product facilities in operation, one under development, and two research centers, SMS has truly graduated in to big league with more than 600 employees working for it.

SMS Pharmaceuticals is an integrated pharma company with business presence in over 70 countries.

SMS is focused on API manufacturing and is the single largest producer of anti ulcer products and is renowned among the clientele for the excellent quality of product and customer service.

The company is diversifying into CRAMS by creating research and manufacturing facilities bettering the requirements of the regulatory markets to appeal to international clientele.

SMS is venturing into highly specialized oncology segment by building first of its kind dedicated oncology API and formulations manufacturing facility in Andhra Pradesh to target the niche market segments.

Merger of Sreenivasa Pharma Private Ltd with SMS Pharmaceuticals Ltd has given a new boost to the company, SMS Pharma has also completed the takeover of Plant Organics.

Recently SMS has established new state of art corporate research center with ultramodern facilities encompassing the whole gamut of research activity viz. from product conception to development, scaling up and DMF preparation. This is supported by well equipped analytical wing and a fully functional pilot plant. This new facility will enhance our existing offerings from a contract research and custom synthesis point of view.

R&D at SMS drives the company’s competitive edge, reflected in the introduction of pioneering products and processes with a superior price-value proposition. Strong R&D has been at the core of SMS growth since its inception. SMS started R&D activities with 4 doctorate scientists supported by 20 senior chemists in a 10000 Sq.ft area.

SMS recently expanded its R&D facilities by creating a state of art corporate research center with infrastructure and expertise to carry out all the activities from product conception to the development, scale up, stability studies culminating in preparation of the DMF.

Product range of the company includes:

  • API and Intermediates
  • Cytotoxic Solid Dose, Sterile Cytotoxic Liquid, and Lyophilized Products
  • Bio Products
  • Inorganic Products
  • Nutraceuticals

Different divisions of the company:

  • Manufacturing :SMS Pharmaceuticals Ltd. is one of the leading pharmaceutical manufacturing companies in India with world-class facilities with a wide range of process equipment fully compliant with WHO GMP standards.SMS has over the years developed tremendous manufacturing facilities to suit its style of operations and to meet the requirements of USFDA and other regulatory markets. A total of 6 facilities are being presently operated and one is under construction.
  • Research and development :R&D at SMS drives the company’s competitive edge, reflected in the introduction of pioneering products and processes with a superior price-value proposition. Strong R&D has been at the core of SMS growth since its inception. SMS started R&D activities with 4 doctorate scientists supported by 20 senior chemists in a 10000 Sq.ft area.SMS recently expanded its R&D facilities by creating a state of art corporate research center with infrastructure and expertise to carry out all the activities from product conception to the development, scale up, stability studies culminating in preparation of the DMF.SMS research team now comprises of about 100 scientists with expertise in process research, analytical research and scale up. A dedicated project management team handles costing, administration, purchase, and project monitoring. R&D capabilities of the company span across reaction technologies, organic compound categories, and novel catalytic systems. This center is capable of delivering top notch contract research modules to international clientele.

Achievements/ recognition :

  • SMS was given the export house status in the year 1997-98.
  • Awarded the Prestigious ' Pandit Jawaharlal Nehru Silver Rolling Trophy' for the best productivity effort in the state.
  • Became the single largest producer of Ranitidine Hydrochloride in the World.
  • One of the leading export houses exporting to more than 70 countries worldwide.
  • WHO-GMP approved API manufacturing facilities in India (2 more to be operational soon).
  • Achieved ISO 9001 certification for Units at Khazipally and Bollaram.
  • Awarded the prestigious US GCNC Green chemistry award.
  • Successfull FDA audits in 2004 and 2008 at our Bachupally unit.
  • Proven expertise in low cost process routes, commercialization & manufacturing.
  • Over 21 process patents and 72 regulatory filings.
  • Successful execution of contract research and manufacturing assignments.
  • CRISIL renews SMS Pharma's SME 1 rating for FY 09-10.
  • Recieved 'Best Industrial Productivity Effort in the State' silver rolling trophy.

Future plan:

SMS is building an ultra modern API manufacturing facility near Vizag on the eastern coast of India to cater to in house production needs and also for the emerging contract manufacturing business.

To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×